Abbott moves to acquire Exact Sciences in major $21 billion all-stock merger

Abbott agreed to acquire Exact Sciences in a $21 billion all-stock deal aimed at expanding its diagnostics capabilities. The combination strengthens Abbott’s position in cancer screening and precision diagnostics, supported by Exact Sciences’ leading test portfolio. Abbott expects the transaction to add nearly $2 billion to revenue by 2027 and deliver meaningful cost synergies. The deal is projected to close by mid-2026 pending shareholder approval and regulatory clearance.